Differential ligand-mediated pituitary somatostatin receptor subtype signaling: Implications for corticotroph tumor therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 11, 2009, Pages 4342-4350

  Ben Shlomo, Anat ^a   Schmid, Herbert ^b   Wawrowsky, Kolja ^a   Pichurin, Oxana ^a   Hubina, Erika ^a   Chesnokova, Vera ^a   Liu, Ning Ai ^a   Culler, Michael ^c   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP; FORSKOLIN; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

ACTH SECRETING ADENOMA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM SIGNALING; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GENE OVEREXPRESSION; HORMONE RECEPTOR INTERACTION; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; SIGNAL TRANSDUCTION; STELLATE CELL; TRANSIENT EXPRESSION; TUMOR CELL;

EID: 70449127649     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1311     Document Type: Article

References (27)

1. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M 2008 Treatment of adrenocorticotropin-dependent Cushing's syndrome: aconsensus statement. J Clin Endocrinol Metab 93:2454-2462 (Pubitemid 352008503)
2. Lamberts SW, Uitterlinden P, Klijn JM 1989 The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 120:760-766 (Pubitemid 19148444)
3. Invitti C, de Martin M, Brunani A, Piolini M, Cavagnini F 1990 Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin). Clin Endocrinol (Oxf) 32: 275-281 (Pubitemid 20063559)
4. Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G 1990 Failure of somatostatin and octreotide to acutely affect the hypothalamic- pituitary-adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 13:257-261 (Pubitemid 20159184)
5. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S 1997 Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99:789-798 (Pubitemid 27097683)
6. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X, Epelbaum J 2003 Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 88: 5353-5360 (Pubitemid 37455411)
7. Zatelli MC, Maffei P, Piccin D, Martini C, Rea F, Rubello D, Margutti A, Culler MD, Sicolo N, degli Uberti EC 2005 Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab 90:2104-2109
8. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716 (Pubitemid 34552506)
9. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, Bruns C 2003 A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 46:2334-2344 (Pubitemid 36637918)
10. Fedele M, De Martino I, Pivonello R, Ciarmiello A, Del Basso De Caro ML, Visone R, Palmieri D, Pierantoni GM, Arra C, Schmid HA, Hofland L, Lombardi G, Colao A, Fusco A 2007 SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin Cancer Res 13:2738-2744 (Pubitemid 46788042)
11. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC 2007 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14:91-102 (Pubitemid 47521725)
12. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J 2009 Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122
13. Ben-Shlomo A, Melmed S 2007 Pasireotide - a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs 10:885-895 (Pubitemid 350179091)
14. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654 (Pubitemid 40575811)
15. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482-4488 (Pubitemid 44833427)
16. Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA 2005 Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 153:R7-R10 (Pubitemid 41410505)
17. Nolan LA, Schmid HA, Levy A 2007 Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Endocrinology 148:2821-2827 (Pubitemid 46984783)
18. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ 2005 Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289:E278-E287 (Pubitemid 41076629)
19. Ben-Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S 2005 Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 280:24011-24021 (Pubitemid 40884889)
20. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S 2009 Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 94:654-661
21. Ben-Shlomo A, Zhou C, Pichurin O, Chesnokova V, Liu NA, Culler MD, Melmed S 2009 Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol 23:337-348
22. Ben-Shlomo A, Pichurin O, Barshop NJ, Wawrowsky KA, Taylor J, Culler MD, Chesnokova V, Liu NA, Melmed S 2007 Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol 21:2565-2578 (Pubitemid 47529366)
23. Schmid HA, Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1):47-50 (Pubitemid 39382369)
24. Reisine T 1984 Somatostatin desensitization: loss of the ability of somatostatin to inhibit cyclic AMP accumulation and adrenocorticotropin hormone release. J Pharmacol Exp Ther 229:14-20 (Pubitemid 14082904)
25. Reisine TD, Takahashi JS 1984 Somatostatin pretreatment desensitizes somatostatin receptors linked to adenylate cyclase and facilitates the stimulation of cyclic adenosine 3′:5′-monophosphate accumulation in anterior pituitary tumor cells. J Neurosci 4:812-819
26. Mahy N, Woolkalis M, Manning D, Reisine T 1988 Characteristics of somatostatin desensitization in the pituitary tumor cell line AtT- 20. J Pharmacol Exp Ther 247:390-396 (Pubitemid 18253725)
27. Elberg G, Hipkin RW, Schonbrunn A 2002 Homologous and heterologous regulation of somatostatin receptor 2. Mol Endocrinol 16:2502-2514 (Pubitemid 35266069)